Biogen Mutual Funds | StatInvestor

Health Care & Life Sciences » Biotechnology | Biogen Inc.

Biogen Inc. | Mutual Funds

Mutual Funds that own Biogen Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Vanguard PRIMECAP Fund

9,221,680

4.58%

15,180

4.68%

06/30/2018

Vanguard Total Stock Market Index Fund

5,303,453

2.63%

21,114

0.25%

07/31/2018

Vanguard 500 Index Fund

3,821,107

1.9%

4,252

0.3%

07/31/2018

Vanguard Health Care Fund

3,592,903

1.78%

2.52%

06/30/2018

ClearBridge Aggressive Growth Fund

3,170,327

1.57%

-14,514

9.07%

12/31/2017

iShares Nasdaq Biotechnology ETF

2,373,169

1.18%

-31,038

8.56%

09/06/2018

Vanguard Capital Opportunity Fund

2,331,100

1.15%

-25,000

4.38%

06/30/2018

SPDR S&P 500 ETF

2,328,846

1.15%

26,908

0.3%

09/06/2018

Vanguard Institutional Index Fund

2,041,057

1.01%

1,990

0.3%

07/31/2018

Government Pension Fund - Global (The)

2,033,992

1.01%

51,141

0.09%

12/31/2017

About Biogen

View Profile

Address	225 Binney Street Cambridge Massachusetts 02142 United States
Employees	-
Website	http://www.biogen.com
Updated	07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.